Eisai Oncology & Helsinn Group to Present New CINV Research at 2014 International Symposium on Supportive Care in Cancer

Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the U.S. and a Representative Office in China. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care.

Helsinn Group in-licenses early-to-late stage new chemical entities, completing their development by performing preclinical and clinical studies and associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn's products are out-licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn's products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers. Further information on Helsinn Group is available at http://www.helsinn.com.

About Eisai Oncology

Eisai Oncology is dedicated to discovering, developing and producing innovative oncology therapies that may make a difference and impact the lives of patients and their families. This passion for people is part of Eisai's human health care (hhc) mission, which strives for better understanding of the needs of patients and their families to help increase the benefits health care provides. Our commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, vaccines, and biologic agents across various types of cancer. For more information about Eisai, please visit http://www.eisai.com/US.

About Eisai Inc.

At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at http://www.eisai.com/US.

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

1. Roscoe JA, Morrow GR, Hickok JT, Stern RM. Nausea and vomiting remain a significant clinical problem: Trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain and Symptom Management. 2000;20(2):113-121.

2. Aapro M et al. Multiple cycle CINV control and safety of NEPA, a capsule containing netupitant and palonosetron administered once per cycle of moderately emetogenic chemotherapy (MEC). MASCC/ISOO 2014 Abstract. June 2014.

3. Hesketh PJ et al. NEPA, a fixed-dose antiemetic combination of netupitant and palonosetron: Results of effectiveness in 407 patients receiving cisplatin plus chemotherapy of various emetic risk. MASCC/ISOO 2014 Abstract. June 2014.

4. Schwartzberg L et al. Do NK1 receptor antagonists (RA) contribute to nausea control? Evaluation of the novel NEPA fixed-dose combination of NK1 RA + 5-HT3 RA from pivotal trials. MASCC/ISOO 2014 Abstract. June 2014.

5. Jordan K et al. Is the addition of an NK1 receptor antagonist beneficial in patients receiving carboplatin? Supplementary data with NEPA, a fixed-dose combination of netupitant and palonosetron. MASCC/ISOO 2014 Abstract. June 2014.

6. Aapro M et al. Safety of NEPA, an oral fixed-dose combination of netupitant and palonosetron: Pooled data from the Phase 2/3 clinical program. MASCC/ISOO 2014 Abstract. June 2014.

7. Faria C et al. Resource utilization and costs associated with nausea in patients experiencing chemotherapy induced nausea and vomiting. MASCC/ISOO 2014 Abstract. June 2014.

8. Gralla R et al. A Phase 3 study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Annals of Oncology. Accessed March 24, 2014: http://annonc.oxfordjournals.org/content....

        
        Eisai Inc.
        Media Inquiries
        Laurie Landau
        Eisai Inc.
        +1-201-746-2510
        laurie_landau@eisai.com

        Helsinn Group
        Paola Bonvicini
        Head of Communication
        & Press Office
        PH +41-91-985-21-21
        info-hhc@helsinn.com

        Investor Inquiries
        Alex Scott
        Eisai Inc.
        +1-201-746-2177
        alex_scott@eisai.com